Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 1/20 | 0.43 |
| ▸ | RIPK1 | Q13546 | 2/20 | 0.40 |
| ▸ | HTR6 | P50406 | 4/20 | 0.39 |
| ▸ | ABL1 | P00519 | 1/20 | 0.39 |
| ▸ | RIN1 | Q13671 | 1/20 | 0.39 |
| ▸ | FURIN | P09958 | 1/20 | 0.39 |
| ▸ | F10 | P00742 | 1/20 | 0.38 |
| ▸ | ENPP3 | O14638 | 6/20 | 0.38 |
| ▸ | ENPP1 | P22413 | 5/20 | 0.38 |
| ▸ | ENPP2 | Q13822 | 4/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | APAF1 | O14727 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | BLM | P54132 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6017758 | 0.92 | ABL1 (0.39) | IDO1HTR6ABL1RIN1ENPP3 | |
| SCHEMBL5036227 | 0.80 | RAB9A (0.53) | RIPK1HTR6ABL1ENPP3ENPP1 | |
| SCHEMBL6018083 | 0.79 | ENPP3 (0.50) | ENPP3ENPP1ENPP2 | |
| SCHEMBL10732064 | 0.79 | PIK3CA (0.47) | IDO1ABL1FURINENPP3ENPP1 | |
| SCHEMBL5040870 | 0.76 | RAB9A (0.53) | RIPK1HTR6ABL1ALDH1A1KDM4E | |
| SCHEMBL5036353 | 0.76 | ENPP3 (0.38) | HTR6ENPP3ENPP1ENPP2MAPT | |
| SCHEMBL5037857 | 0.75 | ENPP3 (0.40) | RIPK1HTR6ENPP3ENPP1ENPP2 | |
| SCHEMBL5037793 | 0.75 | ENPP3 (0.39) | ENPP3ENPP1ENPP2MAPT | |
| SCHEMBL5042961 | 0.75 | HTR6 (0.45) | HTR6TDP1KDM4EMEN1BLM | |
| SCHEMBL5035964 | 0.75 | TP53 (0.42) | RIPK1HTR6ALDH1A1MAPTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7041668-B2 | Substituted benzimidazole compounds and their use for the treatment of cancer | AVENTIS PHARMA S.A. (FR) | 2006-05-09 | — | — | US | disclosed |
| US-20050014811-A1 | Substituted benzimidazole compounds and their use for the treatment of cancer | AVENTIS PHARMA S.A. (FR) | 2005-01-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050014811-A1 | Substituted benzimidazole compounds and their use for the treatment of cancer | CDKL3, CCNL2, CDKL1 | IDO1 232/4885RIPK1 2780/4885HTR6 792/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.